I. Initial combination regimens should include at least one protease inhibitor or non-nucleoside reverse transcriptase inhibitorII. Lamivudine (3TC, Epivir) is highly effective as a single agentIII. Combination antiretroviral therapy has been shown to prolong lifeIV. Combination antiretroviral therapy reduces the incidence of opportunistic infections only for CD4 counts >500/µL
V. The therapeutic regimen should only be changed when viral load levels increase AND when CD4 counts decline
A. I, II and III are true concerning HAART
B. I and III are true concerning HAART
C. II and IV are true concerning HAART
D. Only V is true concerning HAART
E. All of the above statements are true concerning HAART
I. Antiretroviral prophylaxis is recommended for health care workers exposed to HIV+ fluidsII. Combination antiretroviral therapy is recommended to prevent HIV transmissionIII. Combination highly active antiretroviral therapy can completely prevent HIV transmissionIV. Single agents are nearly as effective as combination therapy in preventing HIV transmission
V. Combination therapy to prevent HIV transmission should not include protease inhibitors
A. I, II and III are true concerning anti-retroviral prophylaxis in persons exposed to HIV
B. I and III are true concerning anti-retroviral prophylaxis in persons exposed to HIV
C. II and IV are true concerning anti-retroviral prophylaxis in persons exposed to HIV
D. Only V is true concerning anti-retroviral prophylaxis in persons exposed to HIV
E. All of the above statements are true concerning anti-retroviral prophylaxis in persons exposed to HIV
A. Hepatitis C Virus
B. Hepatitis B Virus
C. Hepatitis A Virus
D. Hepatitis D (Delta) Virus
E. Hairy Cell Leukemia
A. Valacyclovir (Valtrex®)
B. Famciclovir (Famvir®)
C. Ribavirin (Virazole®, others)
D. Cidofovir (Vistide®)
E. Ganciclovir (Cytovene®)
I. Zanamivir (Relenza®)II. Amantadine (Symmetrel®)III. Oseltamivir (Tamiflu®)IV. Rimantidine (Flumadine®)
V. Valganciclovir (Valcyte®)
A. I, II, and III are active against both Influenza A and B
B. I and III are active against both Influenza A and B
C. II and IV are active against both Influenza A and B
D. V alone is active against both Influenza A and B
E. None of the agents above is active against both Influenza A and B
A. Alopecia
B. Bone marrow suppression
C. Nausea and vomiting
D. Neuropathy
E. Mucositis
A. Adriamycin (Doxorubicin®, others)
B. Docetaxel (Taxotere®)
C. Irinotecan (Camptosar®)
D. Carboplatin (Paraplatin®)
E. Ifosfamide (Ifex®)
I. Prostate cancers resistant to one androgen ablation therapy are often sensitive to anotherII. Tamoxifen and raloxifene are selective estrogen response modifiers structurally distinct from estrogenIII. Combination hormonal blockade is currently recommended for the treatment breast cancerIV. Breast cancers resistant to one estrogen ablation therapy are often sensitive to another
V. Pure androgen receptor blockers are often used alone in the treatment of prostate cancer
A. I, II, and III are true concerning hormonal therapy for cancer
B. I and III are true concerning hormonal therapy for cancer
C. II and IV are true concerning hormonal therapy for cancer
D. V alone is true concerning hormonal therapy for cancer
E. None of the statements are true concerning hormonal therapy for cancer
I. Primary neoplasms often have specific chemotherapeutic sensitivitiesII. Tumors which recur following combination chemotherapy are often broadly resistant to other classes of chemotherapuetic agentsIII. Many resistant tumors express pump proteins which pump out various toxins and drugsIV. Resistance to specific chemotherapeutic agents is usually due to point mutations in tumor cell DNA
V. Systemic metabolism of anticancer agents is fairly constant amongst patients, leading to relatively similar systemic levels between patients
A. I, II, and III are true concerning resistance to chemotherapy
B. I and III are true concerning resistance to chemotherapy
C. II and IV are true concerning resistance to chemotherapy
D. V alone is true concerning resistance to chemotherapy
E. None of the statements are true concerning resistance to chemotherapy
aldosteronism [10] ? |